

Immune-related Adverse Events in Patients With Cancer Receiving Influenza Vaccination and Immune Checkpoint Inhibitors

TO THE EDITOR—With interest, we read the study by Chong et al [1] who reported that 20% of patients with cancer who received influenza vaccination concurrently with immune checkpoint inhibitors (ICIs) experienced immune-related adverse events (IRAEs). Their findings were comparable to the rates reported in historical studies and are relatively similar to the rate that we determined in our retrospective analysis (26%) [2]. However, this rate of 20% was not obtained by directly comparing patients from the same prospectively included cohort as we did. The use of historical controls complicates the interpretation of their data, since historical controls receiving ICIs may have received influenza vaccine as well, considering the vaccination coverage of 45–56% among patients with cancer in the United States [3, 4].

In addition, we question the duration of the period of follow-up for IRAEs after influenza vaccination (median, 1.4 years) considering the relatively low immunogenicity of antigens included in the influenza vaccine. The active immune response following influenza vaccination has already waned after a few months and hemagglutination-inhibition titers do not reliably persist year-round in older adults but regress to prevaccination levels in 360 days [5].

Nevertheless, both studies confirm that influenza vaccination during administration of ICIs is safe and that the reported high overall rate of IRAEs (12 of 23, 52%) in the study by Läubli et al [6] with fewer subjects may have been a chance finding. Therefore, seasonal influenza vaccination can still be advocated in patients with cancer receiving ICIs.

Note

Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Geert H. Groeneveld,^{1,2} Dirk H. Wijn,¹ and Albert M. Vollaard²

¹Department of Internal Medicine and Infectious Diseases, Leiden University Medical Center, and ²Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands

References

- Chong CR, Park VJ, Cohen B, Postow MA, Wolchok JD, Kamboj M. Safety of inactivated influenza vaccine in cancer patients receiving immune checkpoint inhibitors (ICI). *Clin Infect Dis* 2020; 70:193–9.
- Wijn DH, Groeneveld GH, Vollaard AM, et al. Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events. *Eur J Cancer* 2018; 104:182–7.
- O'Halloran AC, Lu PJ, Williams WW, Bridges CB, Singleton JA. Influenza vaccination coverage among people with high-risk conditions in the U.S. *Am J Prev Med* 2016; 50:e15–26.
- Lu PJ, O'Halloran A, Ding H, Srivastava A, Williams WW. Uptake of influenza vaccination and missed opportunities among adults with high-risk conditions, United States, 2013. *Am J Med* 2016; 129:e636.e1–11.
- Young B, Zhao X, Cook AR, Parry CM, Wilder-Smith A, I-Cheng MC. Do antibody responses to the influenza vaccine persist year-round in the elderly? A systematic review and meta-analysis. *Vaccine* 2017; 35:212–21.
- Läubli H, Balmelli C, Kaufmann L, et al. Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events. *J Immunother Cancer* 2018; 6:40.

Correspondence: G. H. Groeneveld, Department of Infectious Diseases and Internal Medicine, Leiden University Medical Center, P.O. box 9600, 2300 RC Leiden, The Netherlands (g.h.groeneveld@lumc.nl).

Clinical Infectious Diseases® 2020;70(7):1519

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com DOI: 10.1093/cid/ciz512

Reply to Groeneveld et al

TO THE EDITOR—We appreciate the response by Groeneveld et al [1] to our article [2]. The authors bring up methodological limitations that are fully acknowledged and addressed in our study. There are no reliable estimates of influenza vaccine coverage among patients on immune checkpoint inhibitors (ICIs); the association between vaccine- and immune-related adverse events (IRAEs) remains unexamined in randomized controlled trials. Although key ICI clinical trials permitted inactivated influenza vaccine among enrolled subjects, IRAE rates were not specifically examined by vaccination status. A few recently conducted retrospective studies [2–5], including ours, examined this important clinical question. Despite the variability in study design among these reports, the findings consistently support that flu vaccine is safe and effective in patients on ICI.

With regard to the duration of immunity after influenza vaccine, antibody responses can persist over several seasons [6]. Therefore, we believe the extended follow-up beyond a typical influenza season is a cautious approach. With a median follow-up of 1.4 years, IRAE rates in our cohort remain comparable to historical studies, suggesting that there is even less chance that any IRAEs observed in our cohort of vaccinated patients on anti-programmed cell death protein 1 therapy were related to vaccination. We do not think this impacts our study conclusions. We appreciate the opportunity to clarify these issues.

Note

Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure